<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:02:59 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>Third Quarter 2021 Financial Results | BridgeBio</title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="BridgeBio reported its financial results for the third quarter ended September 30, 2021 and provided an update on the Company’s operations. Learn more!"
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="Third Quarter 2021 Financial Results | BridgeBio"
    />
    <meta
      property="og:description"
      content="BridgeBio reported its financial results for the third quarter ended September 30, 2021 and provided an update on the Company’s operations. Learn more!"
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2021-11-04T19:25:00+00:00"
    />
    <meta
      property="article:modified_time"
      content="2022-06-23T15:36:16+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2019/02/BridgeBio_Share.png"
    />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="600" />
    <meta property="og:image:type" content="image/png" />
    <meta name="author" content="Cybele Gouverneur" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Cybele Gouverneur" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="14 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update/",
            "name": "Third Quarter 2021 Financial Results | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "datePublished": "2021-11-04T19:25:00+00:00",
            "dateModified": "2022-06-23T15:36:16+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/0ccd4f21aad52916b60d0206bb498df7"
            },
            "description": "BridgeBio reported its financial results for the third quarter ended September 30, 2021 and provided an update on the Company’s operations. Learn more!",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update/"
                ]
              }
            ]
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/0ccd4f21aad52916b60d0206bb498df7",
            "name": "Cybele Gouverneur",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g",
              "caption": "Cybele Gouverneur"
            },
            "url": "https://bridgebio.com/author/cybele-gouverneur/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/stylef147.css?ver=1734519240"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-cssf147.css?ver=1734519240"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrustf147.css?ver=1734519240"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scriptsf147.js?ver=1734519240"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modalf147.js?ver=1734519240"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/5232.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../index3322.html?p=5232" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed31e1.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embed2a7c?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-reports-third-quarter-2021-financial-results-and-business-update%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-5232 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma Reports Third Quarter 2021 Financial Results and
              Business Update
            </h1>
            <section>
              <p>
                –<em
                  >Topline results from Part A of the Phase 3 ATTRibute-CM trial
                  of TTR stabilizer for transthyretin amyloid cardiomyopathy
                  (ATTR-CM)</em
                >
                <em>expected by end of 2021</em>
              </p>

              <p>
                –<em>Meaningful progress in RAS cancer portfolio</em>
                <em
                  >with discovery of next-generation KRAS G12C dual inhibitors
                  and </em
                ><em>novel PI3k</em><em>a</em><em>:RAS breakers</em>
              </p>

              <p>
                <em
                  >-Advancements in gene therapy pipeline with first patient
                  dosed in Canavan disease trial and newly announced program
                  targeting classic galactosemia (severe GALT deficiency)</em
                >
              </p>

              <p>
                –<em>Company </em><em>repurchased </em
                ><em
                  >$148.4 million in BridgeBio common stock under 2021 Share
                  Repurchase Program, demonstrating the Company’s confidence in
                  the long-term prospects of its pipeline</em
                >
              </p>

              <p>
                –<em
                  >Ended quarter with $599.6 million in cash, cash equivalents
                  and marketable securities</em
                >
              </p>

              <p>
                PALO ALTO, Calif., NOVEMBER 4, 2021 – BridgeBio Pharma, Inc.
                (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage
                biopharmaceutical company focused on genetic diseases and
                cancers, today reported its financial results for the third
                quarter ended September 30, 2021 and provided an update on the
                Company’s operations.
              </p>

              <p>
                BridgeBio has more than 30 programs in its pipeline for patients
                living with genetic diseases and cancers and 20 ongoing clinical
                trials underway across more than 450 sites around the world.
                Earlier this year BridgeBio received its first two U.S. Food and
                Drug Administration (FDA) drug approvals and has successfully
                filed 15 Investigational New Drug (IND) applications since the
                Company’s founding in 2015.
              </p>

              <p><strong>BridgeBio’s four core value drivers:</strong></p>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Acoramidis (AG10) – Transthyretin (TTR) stabilizer for
                    transthyretin amyloid cardiomyopathy (ATTR-CM):</strong
                  > Topline results from Part A of the Phase 3 ATTRibute-CM
                  trial are expected in late 2021 and from Part B in 2023. The
                  primary endpoint at Part A is the change from baseline in a
                  6-minute walk distance (6MWD) in trial participants receiving
                  acoramidis or placebo after 12 months. If the change from
                  baseline in 6MWD in Part A is highly statistically
                  significant, BridgeBio expects to submit an application for
                  regulatory approval of acoramidis in 2022 to the FDA. The
                  study enrolled more than 600 subjects with either wild-type or
                  variant TTR across more than 80 sites in 18 countries. ATTR-CM
                  is a rare heart condition with a progressive and debilitating
                  impact on quality of life likely affecting more than 400,000
                  patients worldwide.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Encaleret – Calcium-sensing receptor (CaSR) inhibitor for
                    autosomal dominant hypocalcemia type 1 (ADH1):</strong
                  > BridgeBio presented updated Phase 2b data for encaleret in
                  an <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/a47ae107-d7d8-43a0-9350-b5e887fd334f"
                    target="_blank"
                    rel="noreferrer noopener"
                    >oral presentation</a
                  > at the American Society of Bone and Mineral Research (ASBMR)
                  2021 Annual Meeting in October. Within five days of
                  individualized dose titration in 13 participants, encaleret
                  normalized mean blood calcium levels and 24-hour urine calcium
                  excretion. Achieving simultaneous blood and urine calcium
                  normalization is a challenge for patients with ADH1 due to the
                  limitations of current standard-of-care. If approved,
                  encaleret could be the first therapy on the market for ADH1, a
                  condition caused by gain of function variants in the
                  calcium-sensing receptor (<em>CASR</em>) gene estimated to be
                  carried by 12,000 individuals in the United States alone.
                  BridgeBio plans to initiate a Phase 3 registrational trial of
                  encaleret in patients with ADH1 in 2022.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Low-dose infigratinib – FGFR1-3 inhibitor for
                    achondroplasia:</strong
                  > Initial data from the ongoing Phase 2 dose ranging study are
                  expected in the first half of 2022. Achondroplasia is the most
                  common form of genetic short stature and one of the most
                  common genetic diseases, with a prevalence of greater than
                  55,000 cases in the United States and European Union. Low-dose
                  infigratinib is the only known product candidate in clinical
                  development for achondroplasia that is designed to target the
                  disease at its genetic source and the only orally administered
                  product candidate in clinical-stage development.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >BBP-631 – AAV5 gene therapy candidate for congenital
                    adrenal hyperplasia (CAH):</strong
                  >
                  Received Fast Track designation from the FDA in May 2021. IND
                  cleared by the FDA and site activation for initiation of a
                  first-in-human Phase 1/2 study is ongoing, with initial data
                  anticipated in mid-2022. CAH is one of the most prevalent
                  genetic diseases potentially addressable with AAV gene
                  therapy, with more than 75,000 cases estimated in the United
                  States and European Union. The disease is caused by
                  deleterious mutations in the gene encoding an enzyme called
                  21-hydroxylase, leading to lack of endogenous cortisol
                  production. BridgeBio’s AAV5 gene therapy candidate is
                  designed to provide a functional copy of the
                  21-hydroxylase-encoding gene (CYP21A2) and potentially address
                  many aspects of the disease course.
                </li>
              </ul>

              <p>
                <strong>Recent pipeline progress and corporate updates:</strong>
              </p>

              <ul class="wp-block-list">
                <li>
                  <strong>Stock repurchases:</strong> BridgeBio repurchased
                  $148.4 million in BridgeBio common stock under its 2021 Share
                  Repurchase Program, demonstrating the Company’s confidence in
                  the long-term prospects of its pipeline.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong>LianBio IPO and partnership: </strong>China-based
                  partner LianBio raised $325 million in its initial public
                  offering on November 1. BridgeBio is estimated to own
                  approximately 4.7% post-IPO. BridgeBio and LianBio announced
                  in August that the first patient was treated in a Phase 2a
                  trial of infigratinib in patients with gastric cancer and
                  other advanced solid tumors. LianBio in-licensed rights from
                  BridgeBio for infigratinib for development and
                  commercialization in Mainland China, Hong Kong and Macau.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong>RAS cancer portfolio:</strong> BridgeBio announced the
                  discovery of its next-generation KRAS G12C dual inhibitors,
                  the first-known compounds that directly bind and inhibit KRAS
                  in both its active (GTP bound) and inactive (GDP bound)
                  conformations, and PI3ka:RAS breakers, small molecules that
                  block RAS driven PI3Ka activation – a novel approach with the
                  potential to inhibit oncogenic PI3Ka signaling without adverse
                  effects on glucose metabolism. RAS is one of the most
                  well-known oncogenic drivers with approximately 30% of all
                  cancers being driven by RAS mutations, including large
                  proportions of lung, colorectal and pancreatic tumors.
                  BridgeBio expects to select a RAS development candidate in
                  2022.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >BBP-812 – AAV9 gene therapy candidate for Canavan
                    disease:</strong
                  >
                  BridgeBio announced that the first patient was dosed in its
                  Phase 1/2 trial of BBP-812 for Canavan disease. If successful,
                  BridgeBio’s gene therapy could be the first approved
                  therapeutic option for children born with Canavan disease, a
                  devastating and life-threatening condition. An initial Phase
                  1/2 data readout is expected in 2022.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >BBP-818 – AAV gene therapy candidate for classic
                    galactosemia (severe GALT deficiency):</strong
                  > BridgeBio announced a new gene therapy program for classic
                  galactosemia, which is caused by a severe deficiency of the
                  enzyme galactose-1-phosphate uridylyltransferase (GALT),
                  affecting approximately 7,000 patients in the United States
                  and the European Union. Preclinical studies in a mouse model
                  of classic galactosemia have shown that BridgeBio’s BBP-818
                  therapy restored up to 72% of wild-type levels of GALT enzyme
                  in the brain following a single dose.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong>BBP-398 – SHP2 inhibitor</strong>: First publication
                  of preclinical data for BridgeBio’s potentially best-in-class
                  SHP2 inhibitor designed for the treatment of resistant cancer.
                  Data demonstrated activity in non-small cell lung cancer
                  (NSCLC) driven by RAS or other MAPK-pathway activating
                  mutations. The results were featured in a <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/f2395287-1e83-4203-8b05-d3d771b1e599"
                    target="_blank"
                    rel="noreferrer noopener"
                    ><strong>poster presentation</strong></a
                  > shared at the AACR-NCI-EORTC International Conference on
                  Molecular Targets and Cancer Therapeutics in October.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >BBP-418 – Glycosylation substrate for limb-girdle muscular
                    dystrophy type 2i (LGMD2i):</strong
                  > Fast Track designation granted by the FDA<em>. </em>The
                  Phase 2 trial was initiated in patients with LGMD2i in the
                  first quarter of 2021. If successful, BBP-418 could be the
                  first approved therapy for patients with LGMD2i. With
                  approximately 7,000 patients with potentially treatable
                  mutations, LGMD2i is an inherited recessive muscular dystrophy
                  caused by mutation of fukutin-related protein. A Phase 2 data
                  readout is expected in 2022.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >BBP-711 – Glycolate oxidase (GO) inhibitor for
                    hyperoxaluria:</strong
                  > BridgeBio announced preliminary Phase 1 data in which
                  BBP-711 was well-tolerated and resulted in maximal increases
                  in plasma glycolate exceeding those achieved by any
                  GO-targeting agents reported in healthy adult volunteers.
                  BBP-711 is being developed for the treatment of primary
                  hyperoxaluria type 1 (PH1) and hyperoxaluria caused by hepatic
                  overproduction of oxalate in recurrent kidney stone formers. A
                  full readout of Phase 1 data in healthy adult volunteers is
                  expected in 2022, to be followed by initiation of a Phase 2/3
                  trial in PH1 and a Phase 2 proof-of-concept trial in recurrent
                  kidney stone formers.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong>TRUSELTIQ™ (infigratinib)</strong>: Health Canada
                  approved TRUSELTIQ (infigratinib), a small molecule kinase
                  inhibitor that targets fibroblast growth factor receptor
                  (FGFR), under the Notice of Compliance with Conditions (NOC/c)
                  policy, for the treatment of adults with previously treated,
                  unresectable locally advanced or metastatic cholangiocarcinoma
                  (CCA) with a FGFR2 fusion or other rearrangement. BridgeBio’s
                  partner Helsinn Group has exclusive commercial rights for
                  TRUSELTIQ in Canada with BridgeBio eligible for tiered
                  royalties as a percentage of net sales as part of the global
                  collaboration and license agreement entered into between the
                  two companies in March 2021.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong>BridgeBio Pharma R&amp;D Day:</strong> Held a virtual
                  R&amp;D Day on October 12, 2021. Presentation replay can be
                  found on BridgeBio’s investor website
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/events/event-details/bridgebio-pharma-inc-rd-day-0"
                    target="_blank"
                    rel="noreferrer noopener"
                    >here</a
                  >.
                </li>
              </ul>

              <ul class="wp-block-list">
                <li>
                  <strong
                    >Four new independent directors added to BridgeBio’s
                    board:</strong
                  >
                  <ul>
                    <li>
                      <strong>Hannah Valantine, M.D.</strong>, a leader in organ
                      transplant genomics and workforce diversity who is a
                      professor of medicine at Stanford University School of
                      Medicine
                    </li>
                    <li>
                      <strong>Fred Hassan</strong>, a pharmaceutical and
                      financial industry leader who is the former CEO of
                      Schering-Plough and former chairman of Bausch &amp; Lomb
                    </li>
                    <li>
                      <strong>Andrea Ellis</strong>, a consumer technology
                      innovator and the chief financial officer of Lime
                    </li>
                    <li>
                      <strong>Douglas Dachille</strong>, an investment
                      management veteran and the former chief investment officer
                      of American International Group, Inc. (AIG)
                    </li>
                  </ul>
                </li>
              </ul>

              <p><strong>Third Quarter 2021 Financial Results:</strong></p>

              <p>
                <strong
                  >Cash, Cash Equivalents and Marketable Securities</strong
                >
              </p>

              <p>
                Cash, cash equivalents and marketable securities, excluding
                restricted cash, totaled $599.6 million as of September 30,
                2021, compared to $607.1 million as of December 31, 2020. Over
                the past three quarters, the Company repurchased $148.4 million
                in BridgeBio common stock under its 2021 Share Repurchase
                Program and $50.0 million in BridgeBio common stock in
                conjunction with its issuance of the 2029 convertible notes,
                paid $61.3 million for capped call options related to the
                issuance of its 2029 convertible notes and $35.0 million of
                regulatory-related milestone payments in connection with its
                approved products. Earlier during the year, BridgeBio paid $21.3
                million to Eidos shareholders who elected for cash settlement in
                exchange for their Eidos shares and $63.8 million of direct
                transaction costs arising from the merger with Eidos. These were
                offset by cash receipts of $731.4 million in net proceeds from
                the issuance of BridgeBio’s 2029 convertible notes, $65.1
                million from collaboration partner, Helsinn Group, and $25.0
                million in net proceeds from Hercules Capital, Inc. under an
                amended loan agreement. The remaining change primarily related
                to payments of interest and operating costs and expenses.
              </p>

              <p>
                Cash, cash equivalents and marketable securities, excluding
                restricted cash decreased by $298.8 million when compared to
                balance as of June 30, 2021, which was $898.4 million. During
                the quarter, the Company repurchased $143.1 million of BridgeBio
                common stock and paid $35.0 million of regulatory-related
                milestone payments in connection with its approved products.  
              </p>

              <p><strong>Operating Costs and Expenses</strong></p>

              <p>
                Operating costs and expenses for the quarter increased by $23.7
                million to $151.8 million in the current quarter as compared to
                $128.1 million for the same period in the prior year. The
                increase in operating costs and expenses was due to an increase
                in personnel and external costs to support the progression in
                BridgeBio’s research and development programs and staged
                buildout of its commercial organization as part of commercial
                launch readiness activities. This increase in personnel and
                external costs was offset by $12.2 million in reimbursement of
                expenses from the cost sharing arrangement recognized under
                BridgeBio’s License and Collaboration Agreement with Helsinn
                Group. Stock-based compensation for the quarter was $16.1
                million as compared to $17.7 million for the same period in the
                prior year.
              </p>

              <p>
                The Company’s research and development expenses have not been
                significantly impacted by the global COVID-19 pandemic for the
                periods presented. While BridgeBio experienced some delays in
                certain of its clinical enrollment and trial commencement
                activities, it continues to adapt in this unprecedented time to
                enable alternative site, telehealth and home visits, at-home
                drug delivery, as well as mitigation strategies with its
                contract manufacturing organizations. The longer-term impact, if
                any, of COVID-19 on BridgeBio’s operating costs and expenses is
                currently unknown.
              </p>

              <figure class="wp-block-image size-large">
                <img
                  fetchpriority="high"
                  decoding="async"
                  width="1024"
                  height="603"
                  class="wp-image-5240"
                  src="../../wp-content/uploads/2021/11/BBIO_Earnings_1.1-1024x603.png"
                  alt=""
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_1.1-1024x603.png 1024w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_1.1-300x177.png   300w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_1.1-768x452.png   768w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_1.1-1536x904.png 1536w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_1.1.png          2038w
                  "
                  sizes="(max-width: 1024px) 100vw, 1024px"
                />
              </figure>

              <figure class="wp-block-image size-large">
                <img
                  decoding="async"
                  width="1024"
                  height="692"
                  class="wp-image-5241"
                  src="../../wp-content/uploads/2021/11/BBIO_Earnings_2.1-1024x692.png"
                  alt=""
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_2.1-1024x692.png  1024w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_2.1-300x203.png    300w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_2.1-768x519.png    768w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_2.1-1536x1038.png 1536w,
                    https://bridgebio.com/wp-content/uploads/2021/11/BBIO_Earnings_2.1.png           1788w
                  "
                  sizes="(max-width: 1024px) 100vw, 1024px"
                />
                <figcaption>
                  <br />(1) The condensed consolidated financial statements as
                  of and for the year ended December 31, 2020 are derived from
                  the audited consolidated financial statements as of that date.
                </figcaption>
              </figure>

              <p>
                <strong>About BridgeBio Pharma, Inc.<br /></strong
                ><br />BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical
                company founded to discover, create, test and deliver
                transformative medicines to treat patients who suffer from
                genetic diseases and cancers with clear genetic drivers.
                BridgeBio’s pipeline of over 30 development programs ranges from
                early science to advanced clinical trials and its commercial
                organization is focused on delivering the company’s two approved
                therapies. BridgeBio was founded in 2015 and its team of
                experienced drug discoverers, developers and innovators are
                committed to applying advances in genetic medicine to help
                patients as quickly as possible. For more information visit <a
                  href="../../index.html"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                > and follow us on <a
                  href="https://www.linkedin.com/company/bridgebio/"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>LinkedIn</strong></a
                > and <a
                  href="https://twitter.com/BridgeBioPharma"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>Twitter</strong></a
                >.
              </p>

              <p>
                <strong
                  >BridgeBio Pharma, Inc. Forward-Looking Statements</strong
                >
              </p>

              <p>
                This press release contains forward-looking statements.
                Statements in this press release may include statements that are
                not historical facts and are considered forward-looking within
                the meaning of Section 27A of the Securities Act of 1933, as
                amended (the Securities Act), and Section 21E of the Securities
                Exchange Act of 1934, as amended (the Exchange Act), which are
                usually identified by the use of words such as “anticipates,”
                “believes,” “estimates,” “expects,” “intends,” “may,” “plans,”
                “projects,” “seeks,” “should,” “will,” and variations of such
                words or similar expressions. We intend these forward-looking
                statements to be covered by the safe harbor provisions for
                forward-looking statements contained in Section 27A of the
                Securities Act and Section 21E of the Exchange Act. These
                forward-looking statements, including statements relating to the
                clinical and therapeutic potential of our programs and product
                candidates, including our four core value drivers, the
                availability and success of topline results from Part A and Part
                B of our Phase 3 ATTRibute-CM trial of acoramidis, our plans to
                submit an application for regulatory approval of acoramidis, the
                availability and success of additional data from our ongoing
                study of encaleret for ADH1, the timing and success of
                additional trials of encaleret for ADH1, the availability and
                success of initial data from our ongoing Phase 2 study of
                low-dose infigratinib for achondroplasia and our ongoing Phase
                1/2 study of BBP-631 for CAH, our faith in the long-term
                prospects of our pipeline, the success of our continuing
                partnership with LianBio, the timing of our selection of a RAS
                development candidate, the timing and success of our Phase 1/2
                trial of BBP-812 for Canavan disease, the ability of BBP-812 to
                be the first approved therapeutic option for children born with
                Canavan disease, the ability of BBP-418 to be the first approved
                therapy for patients with LGMD2i, the timing and success of the
                Phase 2 trial of BBP-418 in patients with LGMD2i, the
                availability and success of final data from our ongoing Phase 1
                study of BBP-711 for the treatment of PH1, the timing and
                success of additional clinical trials of BBP-711 in PH1 and in
                recurrent kidney stone formers, our eligibility to receive
                future royalty payments under our strategic collaboration with
                the Helsinn Group and the timing of these events, as well as our
                anticipated cash runway, reflect our current views about our
                plans, intentions, expectations and strategies, which are based
                on the information currently available to us and on assumptions
                we have made. Although we believe that our plans, intentions,
                expectations and strategies as reflected in or suggested by
                those forward-looking statements are reasonable, we can give no
                assurance that the plans, intentions, expectations or strategies
                will be attained or achieved. Furthermore, actual results may
                differ materially from those described in the forward-looking
                statements and will be affected by a number of risks,
                uncertainties and assumptions, including, but not limited to,
                initial and ongoing data from our preclinical studies and
                clinical trials not being indicative of final data, the
                potential size of the target patient populations our product
                candidates are designed to treat not being as large as
                anticipated, the design and success of ongoing and planned
                clinical trials, future regulatory filings, approvals and/or
                sales, despite having ongoing and future interactions with the
                FDA or other regulatory agencies to discuss potential paths to
                registration for our product candidates, the FDA or such other
                regulatory agencies not agreeing with our regulatory approval
                strategies, components of our filings, such as clinical trial
                designs, conduct and methodologies, or the sufficiency of data
                submitted, the continuing success of our collaborations,
                potential volatility in our share price and its impact on our
                2021 Share Repurchase Program, potential adverse impacts due to
                the global COVID-19 pandemic such as delays in regulatory
                review, manufacturing and supply chain interruptions, adverse
                effects on healthcare systems and disruption of the global
                economy, as well as those risks set forth in the Risk Factors
                section of our Annual Report on Form 10-K for the year ended
                December 31, 2020, and our other filings with the U.S.
                Securities and Exchange Commission. Moreover, we operate in a
                very competitive and rapidly changing environment in which new
                risks emerge from time to time. These forward-looking statements
                are based upon the current expectations and beliefs of our
                management as of the date of this press release, and are subject
                to certain risks and uncertainties that could cause actual
                results to differ materially from those described in the
                forward-looking statements. Except as required by applicable
                law, we assume no obligation to update publicly any
                forward-looking statements, whether as a result of new
                information, future events or otherwise.
              </p>

              <p>
                <strong>BridgeBio Media Contact:</strong><br />Grace Rauh<br /><a
                  href="../../cdn-cgi/l/email-protection.html#d89faab9bbbdf6aab9adb098baaab1bcbfbdbab1b7bcbdaef6afa8bdb6bfb1b6bdf6bbb7b5"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong
                    ><span
                      class="__cf_email__"
                      data-cfemail="94d3e6f5f7f1bae6f5e1fcd4f6e6fdf0f3f1f6fdfbf0f1e2bae3e4f1faf3fdfaf1baf7fbf9"
                      >[email&#160;protected]</span
                    ></strong
                  ></a
                ><br />(917) 232-5478
              </p>

              <p>
                <strong>BridgeBio Investor Contact:</strong><br />Katherine
                Yau<br /><a
                  href="../../cdn-cgi/l/email-protection.html#a9c2c8ddc1ccdbc0c7cc87d0c8dce9cbdbc0cdcecccbc0c6cdccdf87ded9ccc7cec0c7cc87cac6c4"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong
                    ><span
                      class="__cf_email__"
                      data-cfemail="2a414b5e424f5843444f04534b5f6a4858434e4d4f4843454e4f5c045d5a4f444d43444f04494547"
                      >[email&#160;protected]</span
                    ></strong
                  ></a
                > <br />(516) 554-5989
              </p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4>
              <a href="../archive/index.html" class="red uppercase"
                >News Archive</a
              >
            </h4>
            <small class="date">11.04.2021</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#20494e464f6042524944474542494f0e434f4d"
              ><span
                class="__cf_email__"
                data-cfemail="d2bbbcb4bd92b0a0bbb6b5b7b0bbbdfcb1bdbf"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
